News
Press ReleaseRevive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
Revive Therapeutics provides an update on its DRDC-led study evaluating Bucillamine as a potential nerve agent treatment, with final findings pending authorization.
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Revive Therapeutics provides an update on its DRDC-led study evaluating Bucillamine as a potential nerve agent treatment, with final findings pending authorization.
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Revive Therapeutics provides an update on its DRDC-led study evaluating Bucillamine as a potential nerve agent treatment, with final findings pending authorization.
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Revive Therapeutics provides an update on its DRDC-led study evaluating Bucillamine as a potential nerve agent treatment, with final findings pending authorization.
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Revive Therapeutics provides an update on its DRDC-led study evaluating Bucillamine as a potential nerve agent treatment, with final findings pending authorization.
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
Revive Therapeutics closes second tranche of private placement, issuing 4,352,381 units at $0.021 per unit to raise $91,400 for working capital and payables.